Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Seth Klarman Gains Stake In Akebia Therapeutics
Hedge Funds

Seth Klarman Gains Stake In Akebia Therapeutics

by forbes.com posted 3months ago 268 views
Klarman's Kleryx holding transitions into stake in fully integrated kidney care company with investor's approval. : Seth Klarman is head of the highly successful hedge fund The Baupost Group LLC. Photographer: Jeenah Moon/Bloomberg© 2018 Bloomberg Finance LP disclosed Thursday that his long-term stake in kidney care company Keryx Biopharmaceuticals closed as it converted into a stake in Akebia Therapeutics upon the merger of the two companies. Klarman’s Baupost portfolio contained 25,791,678 shares of Keryx at third-quarter end, equating to a 21.4% stake in the company.

In this article